Human Growth Hormone Market Overview
- In 2023, human growth hormone market was estimated to be worth USD 6.33 Billion.
- By 2034, the target market is expected to grow to USD 18.3 Billion.
- Target market is expanding at a CAGR of 12.4%
Market Overview:
Human Growth Hormone Market is driven by growing awareness of growth hormones and increased utilization for the treatment of hormonal imbalance disorders. In addition, increasing incidence of growth hormone deficiencies and high R&D investment and methodologies for transforming treatment practices are another factors propelling growth of the global market. Furthermore, technological advancements which increases the efficiency and cost-effectiveness of production is also anticipated to create opportunities for growth of the global market over the forecast period.
Key Takeaways:
- North America held the largest share of the market in 2024.
- Europe is projected to be the fastest-growing market in the coming years.
- By route of administration, subcutaneous segment holds the largest share of the market.
- By application, growth hormone deficiency segment holds the largest share of the market.
- By distribution channel, hospital pharmacy is expected to dominate the target market growth.
To Know More, Request Free Sample Report
Human Growth Hormone Market Dynamics
Key Drivers of Target Market:
Triggers Growth in Tissue as well as Organ in Human Body
Human growth hormone triggers growth in nearly every tissue and organ in your body. However, it’s most well-known for its growth-promoting effect on cartilage and bone, especially in the adolescent years during puberty. Cells in cartilage called chondrocytes and cells in bones which receive signals from HGH to increase replication and thus allow for growth in size. HGH helps to maintain normal body structure throughout the rest of your life.
Restrains:
Side Effects of Synthetic Human Growth Hormone
The use of synthetic human growth hormone for medical treatment can cause certain side effects such as carpal tunnel syndrome, increased insulin resistance or Product 2 diabetes, swelling in arms or legs, joint and muscle pain, enlargement of breast tissue, increased risk of certain cancers, etc.
- Counterbalance Statements: Natural ways to boost human growth hormones are exercise, getting enough sleep, arginine supplements, as well as fasting.
Opportunities:
New Innovations and Technological Advancements
Current innovative treatment approaches relate to personalizing conventional rhGH, developing long-acting GH preparations, the prospect of gene therapy, GH–GH receptor antagonists are expecting for growth of the market in forecast period.
- For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. announced that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone
Human Growth Hormone Market Segmentation
The market is segmented based on Product, Route of Administration, Application, Distribution Channels, and Region.
By Product |
By Route of Administration |
By Application |
By Distribution Channels |
|
|
|
|
Product Insights:
On the basis of product human growth hormone market is segmented into Long Acting, and Others (Short Acting, Intermediate Acting). Long Acting segment dominate the target market growth due to advantages.
Route of Administration Insights:
The human growth hormone market by route of administration is segmented into Subcutaneous, Intramuscular, and Intravenous. Subcutaneous segment holds the largest share of the market due to significant growth rates, and majority of drugs administered through it.
- For Instance, in September 2021, The US Food and Drug Administration (FDA) has approved lonapegsomatropin (Skytrofa, Ascendis Pharma), the first weekly subcutaneous injectable growth hormone for children with growth hormone deficiency (GHD).
Application Insights:
The human growth hormone market by application is segmented into Growth Hormone Deficiency (GHD), Adult GH Deficiency, pediatric GH Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, and Others. Growth hormone deficiency segment holds the largest share of the market due to increasing awareness regarding early diagnosis and treatment.
- For Instance, in June 2024, according to the findings from OraGrowtH210 trial, an oral medication which stimulates the growth hormone secretagogue receptor 1a induced height velocity increases similar to those seen with recombinant human GH for children with pediatric GH deficiency.
Distribution Insights:
The human growth hormone market by distribution is segmented into Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy, and Specialty Pharmacy. Hospital pharmacy is expected to dominate the target market growth due to widespread usage.
Regional Insights
North America: This region is expected to dominate the growth of the market during forecast period due to growing healthcare awareness among people, significant government initiatives, increasing R&D activities, presence of organizations, etc.
Europe: This region is considered to be the fastest growing region in the target market due to increasing burden of growth hormone deficiencies, the availability of artificial growth hormones, extensive research and development activities, etc.
Human Growth Hormone Market Report Scope:
Attribute |
Details |
Market Size 2024 |
USD 7.0 Billion |
Projected Market Size 2034 |
USD 18.3 Billion |
CAGR Growth Rate |
12.4% (2024-2034) |
Base year for estimation |
2023 |
Forecast period |
2024 – 2034 |
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels, analyzing industry trends and opportunities across sub-segments from 2024 to 2034. It segments the market by Product, Route of Administration, Application, Distribution, and Region.
Segmentation:
By Product:
- Long Acting
- Others
- Short Acting
- Intermediate Acting
By Route of Administration:
- Subcutaneous
- Intramuscular
- Intravenous
By Application:
- Growth Hormone Deficiency (GHD)
- Adult GH Deficiency
- Pediatric GH Deficiency
- Turner Syndrome
- Idiopathic Short Stature
- Prader-Willi Syndrome
- Small For Gestational Age
- Others
By Distribution:
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Specialty Pharmacy
By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Human Growth Hormone Market Key Players
The key players operating in the Human Growth Hormone Market Include Novo Nordisk, ELI LILLY CANADA INC., Pfizer Inc., Genetech, Inc., Merck KGaA, Ferring, Teva Pharmaceutical Industries Ltd., Aliyun.com, Changchun GeneScience Pharmaceutical Co., Ltd., Ascendis Pharma, PatSnap, F. Hoffmann-La Roche Ltd., and Sandoz AG.
To Access More Companies, Download Free Sample PDF
Human Growth Hormone Market Key Issues Addressed
- In January 2024, a study conducted by researchers at the University of São Paulo (USP) in Brazil has produced a deeper understanding of the role of GH in mitigating anxiety and, for the first time, identified the population of neurons responsible for modulating the influence of GH on the development of neuropsychiatric disorders involving anxiety, depression and post-traumatic stress.
Analyst View:
The industry is placed for substantial growth due to growing awareness of growth hormones and increased utilization for the treatment of hormonal imbalance disorders, increasing incidence of growth hormone deficiencies and high R&D investment and methodologies for transforming treatment practices. New innovations and development, advance technologies as well as many collaborations and partnerships helps to boost the growth of the market in upcoming years.
More Related Reports
Hormone Replacement Therapy Market
Bio-identical hormone replacement market
Stem Cell Assay Market
Recombinant DNA technology Market
Human Machine Interface Market
Human Growth Hormone Market Company Profile
- Novo Nordisk
- ELI LILLY CANADA INC.
- Pfizer Inc.
- Genetech, Inc.
- Merck KGaA
- Ferring
- Teva Pharmaceutical Industries Ltd.
- Aliyun.com
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Ascendis Pharma
- PatSnap
- F. Hoffmann-La Roche Ltd.
- Sandoz AG.
Human Growth Hormone Market Highlights
FAQs
Human Growth Hormone Market Size was valued at USD 7.0 Billion in 2024 and is expected to reach USD 18.3 Billion by 2034 growing at a CAGR of 12.4%.
The Market is segmented into Product, Route of Administration, Application, Distribution Channels, and Region.
The Market is segmented by region North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. North America is expected to dominate the Market.
The key players operating in the Human Growth Hormone Market Include Novo Nordisk, ELI LILLY CANADA INC., Pfizer Inc., Genetech, Inc., Merck KGaA, Ferring, Teva Pharmaceutical Industries Ltd., Aliyun.com, Changchun GeneScience Pharmaceutical Co., Ltd., Ascendis Pharma, PatSnap, F. Hoffmann-La Roche Ltd., and Sandoz AG.